Bayer NZ announces head of new division

Bayer NZ announces head of new Bayer Schering Pharma division

Auckland, 3 April 2007 Nancy Lam, formerly head of Schering in Hong Kong, has been appointed country division head of the new Bayer Schering Pharma business in New Zealand.

The creation of Bayer Schering Pharma follows the global acquisition by Bayer AG of Schering AG late last year.

Lam has a broad range of experience in the pharmaceutical industry. She trained as a registered pharmacist in the UK before returning to Hong Kong to work in several sales and marketing roles for various pharmaceutical companies.

She joined Schering in Hong Kong as Marketing and Sales Director in 2000, before becoming the head of the business two years later.

Lam says she is thrilled to have been appointed to the New Zealand role and is looking forward to contributing what she has learnt over the years to growing the Bayer Schering Pharma business in New Zealand.

“Before the acquisition by Bayer, Schering New Zealand held a very strong position and indeed was the market leader in the categories of gynaecology and specialised therapeutics.

“It will be very important that now we have merged with Bayer that this position is further strengthened. We will seek out new, untapped opportunities to develop, and will build our infrastructure in order to maximise these opportunities. We will also forge stronger partnerships with key opinion leaders and strive to become a more active player in therapeutic areas.”

Lam says the creation of Bayer Schering Pharma brings together more products and business opportunities, and at the same time allows Bayer to build an organisation with the best people, best processes and best practices.
Key brands for the new Bayer Schering Pharma business include Betaferon®, Kogenate® FS, Yasmin®, Mirena® and Levitra®.

In New Zealand, Bayer Schering Pharma trades as a Bayer HealthCare division of Bayer New Zealand Ltd. The company is based on Auckland’s North Shore.

Ends

Bayer Healthcare

Bayer New Zealand Ltd is part of the worldwide operations of Bayer HealthCare AG, a subsidiary of Bayer AG. Bayer HealthCare AG combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals division. The Pharmaceuticals division is primarily organised in a worldwide leading specialty pharmaceutical company under the name of Bayer Schering Pharma AG, Berlin, Germany. Its research and business activities are focused on the following areas: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology, Primary Care, and Oncology. With innovative products, Bayer Schering Pharma AG aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma AG aims to make a contribution to medical progress and strives to improve the quality of life.

In New Zealand, Bayer aims to make a positive contribution to the community, not only by providing innovative health care solutions, but also through our educational partnerships. For example, Bayer HealthCare supports ongoing clinical research and educational initiatives in the treatment of haemophilia. On a broader scale, we believe social commitment also extends to the environment. We support initiatives to preserve and protect New Zealand’s native flora and fauna, such as the Bayer Kiwi Incubation Unit in Whangarei; and sponsorship of the BAYERBoost Environmental Scholarship Scheme for students.

For more information: www.bayer.co.nz

ENDS

© Scoop Media